The fastest-growing areas for LATAM’s next-generation sequencing market Thu, 21st Apr 2022 Article tags In-vitro diagnosticsNext Generation Sequencing (NGS)AmericasIVD GatewayNext Generation Sequencing (NGS) Latin America’s (LATAM) next-generation sequencing (NGS) market is expected to be the fastest-growing segment in the region’s in-vitro diagnostics (IVD) market between 2022 and 2025. As demand for NGS testing in cancer diagnosis and genetic screening is set to rise, businesses looking to expand in the region could prioritise supporting laboratories to improve their NGS-testing capabilities. We estimate that NGS markets in LATAM countries will grow at a compound annual growth rate (CAGR) of between 5.8 and 15.7% between 2022 and 2025. Explore our key forecasts to stay ahead of market changes and inform your mid-term strategy. Key forecasts for 2022‒2025 Next-generation sequencing is expected to be the fastest-growing IVD market segment in most LATAM countries including Brazil, Mexico, and ColombiaThe sequencing instrument market is expected to grow moderately—investment and instrument costs prevent significant growth in the regionThe sample-preparation instruments and reagents market is expected to grow in line with overall NGS growth—laboratories are likely to focus on affordable automation solutions and improving sample-processing speedsNon-invasive prenatal testing (NIPT) is expected to experience slow growth. It is more expensive than other methods and remains unaffordable for most of the populationOncology testing will experience strong growth because of rising cancer rates in the region and the increasing availability of NGS oncology tests in key markets. However, this type of testing is expensive and will only be accessible to higher-income groupsGenetic testing is also expected to experience strong growth due to increasing reimbursement in key markets. For example, the Brazilian Public Health System covers the cost of exome analysis and NGS tests for rare diseases Infectious diseases testing makes up a relatively small proportion of NGS tests. The majority of demand is expected to go to Covid-19 testing over the forecast period Growing Your NGS Business in LATAM As the region’s NGS market continues to evolve, Clearstate’s IVD Gateway data solution can help you identify opportunities for your organisation. Understand where and how to gain market share with insights to support your strategic and practical business planning. IVD Gateway Size and Share Plus tracks market size, share and growth in 38 countries annually. Find out more about IVD Gateway and how it can help your business. Thu, 21st Apr 2022 Article tags In-vitro diagnosticsNext Generation Sequencing (NGS)AmericasIVD GatewayNext Generation Sequencing (NGS)